{
      "userid": 1,
      "official_url": "https://mjstjournal.com/index.php/mjst/article/view/5814",
      "subjects": [
        "CAR-T hujayra terapiyasi",
        "timus giperplaziyasi",
        "thymic rebound",
        "o\u02bbtkir limfoblastik leykemiya",
        "timus morfologiyasi"
      ],
      "ispublished": "pub",
      "date_type": "published",
      "metadata_visibility": "show",
      "note": "Imported from MJST Journal (OAI id oai:ojs.pkp.sfu.ca:article/5814)",
      "date": "2025-11-24",
      "uri": "https://arxiv.universalpublishings.com/id/eprint/63803",
      "type": "article",
      "full_text_status": "none",
      "id_number": "oai:ojs.pkp.sfu.ca:article/5814",
      "keywords": "CAR-T hujayra terapiyasi; timus giperplaziyasi; thymic rebound; o\u02bbtkir limfoblastik leykemiya; timus morfologiyasi",
      "sword_depositor": 1,
      "dir": "disk0/00/06/38/03",
      "publication": "Multidisciplinary Journal of Science and Technology",
      "lastmod": "2026-05-26 15:54:24",
      "eprint_status": "archive",
      "title": "CAR-T HUJAYRA TERAPIYASINING BOLALAR VA YOSH KATTALARDAGI O\u02bbTKIR LIMFOBLASTIK LEYKEMIYADA TIMUSNING MORFOLOGIK VA MORFOMETRIK XUSUSIYATLARIGA TA\u02bcSIRI: SISTEMATIK TAHLIL VA META-TAHLIL",
      "status_changed": "2026-05-26 15:54:24",
      "abstract": "Ushbu keng qamrovli sistematik tahlil va meta-tahlil o\u02bbtkir limfoblastik leykemiya (O\u02bbLL) bilan kasallangan bolalar va yosh kattalarda (2\u201326 yosh) CD19-, CD22-, dual va allogeneic CAR-T hujayra terapiyasidan keyin timusning morfologik va morfometrik o\u02bbzgarishlarini baholaydi. PRISMA 2020 yo\u02bbriqnomasiga to\u02bbliq rioya qilingan holda, 2025 yil 15 noyabrga qadar chop etilgan 23 tadqiqot (jami 1 846 bemor, shundan 1 423 nafari tisagenlecleucel olgan) kiritildi [1,7,9,18]. Random-effects model bo\u02bbyicha thymic rebound/hyperplasia chastotasi 76,8% (95% CI: 71,4\u201381,6%; I\u00b2=93%), yoshroq bemorlarda (<16 yosh, 1 289 bemor) 88,7% (95% CI: 84,2\u201392,1%) ga yetdi. Timus hajmining standartlashtirilgan o\u02bbrtacha farqi (SMD) +5,1 baravar (95% CI: 4,6\u20135,7; I\u00b2=91%, p<0,001; 19 tadqiqot, 1 623 bemor). Gistologik subguruh (12 tadqiqot): Ki-67 indeksi o\u02bbrtacha 52% (95% CI: 47\u201357%), Hassall tanachalari soni 3,2 baravar (95% CI: 2,8\u20133,6). Rebound+ guruhda 3 yillik EFS HR=0,28 (95% CI: 0,21\u20130,37; I\u00b2=82%), RFS HR=0,31 (95% CI: 0,23\u20130,42); og\u02bbir infektsiya RR=0,32 (95% CI: 0,25\u20130,41). Subguruh tahlili yosh, B-ALL fenotipi, og\u02bbir limfodepletsiya va CAR-T persistentsiyasi bilan reboundning kuchli bog\u02bbliqligini tasdiqladi. Thymic rebound immun rekonstitutsiyaning eng ishonchli biomarkeridir va klinik monitoringda majburiy qo\u02bbllanilishi kerak.",
      "creators": [
        {
          "name": {
            "lineage": null,
            "family": "Ruzieva",
            "given": "Maftuna",
            "honourific": null
          }
        },
        {
          "name": {
            "honourific": null,
            "given": "Dilshod",
            "lineage": null,
            "family": "Allaberganov"
          }
        }
      ],
      "eprintid": 63803,
      "rev_number": 1,
      "datestamp": "2026-05-26 15:54:24",
      "publisher": "Center for Tech and Media Research"
    }